<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923478</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-M201-101</org_study_id>
    <nct_id>NCT03923478</nct_id>
  </id_info>
  <brief_title>ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201
      in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing
      treatment with mesalamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center randomized, double-blind, placebo-controlled study will evaluate the safety
      of ABI-M201 and its effects on disease activity measures in men and women with
      mildly-to-moderately active UC and ongoing treatment with mesalamine. The study will consist
      of 2 sequential, non-overlapping participant cohorts, separated by intervening interim
      analysis (IA). Both cohorts will involve 8-weeks of study drug treatment. Interim data from
      the initial treatment cohort (Cohort A) will inform decision to advance to the subsequent
      second cohort (Cohort B) and its dose selection. 20 subjects will be randomized to cohort A
      (1:1 allocation) and receive treatment with 1 capsule per day of ABI-M201 versus Placebo. 24
      subjects will be randomized to cohort B (3:1 allocation) and receive treatment with up to 5
      capsules one time a day of ABI-M201 versus Placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, placebo-controlled trial involving two sequential non-overlapping cohorts, with intervening interim analysis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>8-weeks</time_frame>
    <description>[Safety]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Laboratory Abnormalities</measure>
    <time_frame>8-weeks</time_frame>
    <description>[Safety]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>8-weeks</time_frame>
    <description>[UC Disease Activity]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Improvement</measure>
    <time_frame>8-weeks</time_frame>
    <description>[UC Disease Activity]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Ulcerative Colitis Chronic Mild</condition>
  <condition>Ulcerative Colitis Chronic Moderate</condition>
  <arm_group>
    <arm_group_label>ABI-M201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: 1 capsule one time a day
Cohort B: 1- 5 capsules one time a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A: 1 capsule one time a day
Cohort B: 1-5 capsules one time a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-M201</intervention_name>
    <description>Active Treatment</description>
    <arm_group_label>ABI-M201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control Treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of UC for at least 3 months prior to screening, with minimum
             disease extent of 15 cm from the anal verge

          -  Mildly to moderately active UC

          -  Inadequate response to ongoing treatment with oral mesalamine ≥2.4 g/day for ≥4 weeks
             from screening visit

        Exclusion Criteria:

          -  Possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory
             bowel disorders

          -  Ongoing or failed prior treatment for UC with methotrexate, azathioprine,
             6-mercaptopurine, cyclosporine, tofacitinib, mycophenolate mofetil, sirolimus
             (rapamycin), thalidomide, tacrolimus (FK-506), or biologics (e.g.,
             TNF-alpha-antagonists, anti-integrin therapies, or agents targeting IL-12 or IL-23,
             etc.)

          -  Any immunosuppressive condition or treatment with immunosuppressive medications

          -  History of prior surgical intervention in any region of the gastrointestinal tract
             (excluding minor surgery)

          -  Prior diagnosis of any cardiovascular, renal, hepatic, endocrine, infectious,
             hematological, oncologic, neuro-psychiatric or immune-mediated disorder, which in the
             opinion of the Principal Investigator might impact the subject's safety or compliance,
             or the interpretation of results

          -  Treatment with any other investigational drugs ≤12 weeks prior to baseline visit

          -  The participant has a condition or is in a situation which, in the Principal
             Investigator's opinion, may put the participant at significant risk, may confound the
             study results, or may interfere significantly with the participant's participation in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tami Warren</last_name>
    <phone>1-843-614-9208</phone>
    <email>TamiWarren@inclin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>510-444-3297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>650-596-8800</phone>
      <phone_ext>19</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-296-1896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>318-631-9121</phone>
      <phone_ext>3454</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>586-598-3329</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-714-0523</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-626-1776</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-870-5599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-284-9709</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>937-320-5050</phone>
      <phone_ext>3070</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-414-5027</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-932-6446</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-409-2040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-452-0569</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>414-805-7181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>403-210-7013</phone>
    </contact>
    <contact_backup>
      <phone>403-399-9790</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>204-787-2060</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator Site)</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L854K1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>905-521-2100</phone>
      <phone_ext>73601</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>(Investigator site)</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3C 5K6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>705-566-0005</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1B</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo Controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

